MedTrace Logo

Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes

NCT00771680 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10408

Last updated 2016-10-28

No results posted yet for this study

Summary

This study is conducted in Europe and Asia. The aim of this observational study is to evaluate the effectiveness and the incidence of serious adverse reactions while using Levemir®, NovoMix® and/or NovoRapid® in subjects with type 2 diabetes that have not used insulin previously under normal clinical practice conditions.

Conditions

Interventions

DRUG

insulin detemir

Start dose and frequency at the discretion of the physician following clinical practice

DRUG

biphasic insulin aspart 30

Start dose and frequency at the discretion of the physician following clinical practice

DRUG

insulin aspart

Start dose and frequency at the discretion of the physician following clinical practice

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00771680 on ClinicalTrials.gov